Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis

References

• Kett DH, Azoulay E, Echeverria PM, et al. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011 Apr 1;39(4):665–670.
   PubMed Web of Science ®Google Scholar
• Klingspor L, Tortorano AM, Peman J, et al. Invasive Candida infections in surgical patients in intensive care units: a prospective, multicentre survey initiated by the European Confederation of Medical Mycology (ECMM)(2006–2008). Clin Microbiol Infect. 2015 Jan 31;21(1):87–e1.
   PubMedGoogle Scholar
• Leleu G, Aegerter P, Guidet B. Systemic candidiasis in intensive care units: a multicenter, matched-cohort study. J Crit Care. 2002 Sep 30;17(3):168–175.
   PubMed Web of Science ®Google Scholar
• Gudlaugsson O, Gillespie S, Lee K, et al. Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis. 2003 Nov 1;37(9):1172–1177.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Sulim S, Holm A, et al. diagnostic issues, clinical characteristics and outcome for patients with fungaemia. J Clin Microbiol. 2011 Jun 29: JCM-00179.
   Web of Science ®Google Scholar
• Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011 Feb 1;55(2):532–538.
   PubMed Web of Science ®Google Scholar
• Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008–2013: results from population-based surveillance. PLoS One. 2015 Mar 30;10(3):e0120452.
   PubMed Web of Science ®Google Scholar
• Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005 Sep 1;49(9):3640–3645.
   PubMed Web of Science ®Google Scholar
• Grim SA, Berger K, Teng C, et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. J Antimicrob Chemother. 2011 Dec 18;67(3):707–714.
   PubMed Web of Science ®Google Scholar
• Kollef M, Micek S, Hampton N, et al. Septic shock attributed to candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012 Mar 15;54(12):1739–1746.
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012 Apr 15;54(8):1110–1122.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of candida diseases 2012: non‐neutropenic adult patients. Clin Microbiol Infect. 2012 Dec 1;18(s7):19–37.
   PubMedGoogle Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2015 Dec 16;62(4):e1–e50.
   PubMedGoogle Scholar
• Limper AH, Knox KS, Sarosi GA, et al. American Thoracic Society documents an official American Thoracic Society Statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96.
   PubMed Web of Science ®Google Scholar
• Póvoa P, Gonçalves-Pereira J. Treatment of candidemia in adult patients without neutropenia-an inconvenient truth. Crit Care. 2011 Jan 31;15(1):114.
   PubMed Web of Science ®Google Scholar
• Chandrasekar P. Management of invasive fungal infections: a role for polyenes. J Antimicrob Chemother. 2010 Dec 14;66(3):457–465.
   PubMed Web of Science ®Google Scholar
• European committee on antimicrobial susceptibility testing. 2015. Clinical breakpoints—fungi (v 9.0).
   Google Scholar
• Di Bonaventura G, Spedicato I, Picciani C, et al. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent candida species from patients with hematologic malignancies. Antimicrob Agents Chemother. 2004 Nov 1;48(11):4453–4456.
   PubMed Web of Science ®Google Scholar
• Cantón E, Pemán J, Gobernado M, et al. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother. 2004 Jul 1;48(7):2477–2482.
   PubMed Web of Science ®Google Scholar
• GRADEWorkingGroup.org [Internet]; [Cited 2017 October 30]. Available from http://www.gradeworkinggroup.org
   Google Scholar
• Bassetti M, Righi E, Ansaldi F, et al. A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Med. 2015 Sep 1;41(9):1601–1610.
   PubMed Web of Science ®Google Scholar
• DiNubile MJ, Hille D, Sable CA, et al. Invasive candidiasis in cancer patients: observations from a randomized clinical trial. J Infect. 2005 Jun 30;50(5):443–449.
   PubMed Web of Science ®Google Scholar
• DiNubile MJ, Lupinacci RJ, Strohmaier KM, et al. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial. J Crit Care. 2007 Sep 30;22(3):237–244.
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002 Dec 19;347(25):2020–2029.
   PubMed Web of Science ®Google Scholar
• Dupont BF, Lortholary O, Ostrosky-Zeichner L, et al. Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B. Crit Care. 2009 Oct 5;13(5):R159.
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, Da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomized double-blind trial. Lancet. 2007 May 11;369(9572):1519–1527.
   PubMed Web of Science ®Google Scholar
• Arnold CJ, Johnson M, Bayer AS, et al. Candida infective endocarditis: an observational cohort study with a focus on therapy. Antimicrob Agents Chemother. 2015 Feb 2: AAC-04867.
   Web of Science ®Google Scholar
• Leroy O, Gangneux JP, Montravers P, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005–2006). Crit Care Med. 2009 May 1;37(5):1612–1618.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet. 2005 Oct 28;366(9495):1435–1442.
   PubMed Web of Science ®Google Scholar
• Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the international collaboration on endocarditis–prospective cohort study. Arch Intern Med. 2009 Mar 9;169(5):463–473.
   PubMedGoogle Scholar
• Pfaller MA, Messer SA, Moet GJ, et al. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY antimicrobial surveillance program (2008–2009). Int J Antimicrob Agents. 2011 Jul 31;38(1):65–69.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012 Apr 1;50(4):1199–1203.
   PubMed Web of Science ®Google Scholar
• Whaley SG, Berkow EL, Rybak JM, et al. Azole antifungal resistance in Candida albicans and emerging non-albicans candida species. Front Microbiol. 2017 Jan;12(7):2173.
   Google Scholar
• Favel A, Michel-Nguyen A, Chastin C, et al. In-vitro susceptibility pattern of candida lusitaniae and evaluation of the Etest method. J Antimicrob Chemother. 1997 May 1;39(5):591–596.
   PubMed Web of Science ®Google Scholar
• Alexander BD, Perfect JR. Antifungal resistance trends towards the year 2000. Drugs. 1997 Nov 1;54(5):657–678.
   PubMed Web of Science ®Google Scholar
• Favel A, Michel-Nguyen A, Peyron F, et al. Colony morphology switching of candida lusitaniae and acquisition of multidrug resistance during treatment of a renal infection in a newborn: case report and review of the literature. Diagn Microbiol Infect Dis. 2003 Sep 30;47(1):331–339.
   PubMed Web of Science ®Google Scholar
• Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a review of the literature. Clin Microbiol Rev. 2018 Jan 1;31(1):e00029–17. (Wayne PA. Clinical and laboratory standards institute. Performance standards for antimicrobial susceptibility testing. 2007; 17.
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Prakash A, Meletiadis J, et al. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017 Jun 1;61(6):e00485–17.).
   Web of Science ®Google Scholar
• Krishna R, Amuh D, Lowder CY, et al. Should all patients with candidaemia have an ophthalmic examination to rule out ocular candidiasis? Eye. 2000 Jan 1;14(1):30.
   PubMedGoogle Scholar
• Shah CP, McKey J, Spirn MJ, et al. Ocular candidiasis: a review. Br J Ophthalmol. 2008 Apr 1;92(4):466–468.
   PubMed Web of Science ®Google Scholar
• W. Price K, Tsui E, Barbazetto I, et al. Ocular involvement in patients with fungemia in an Urban Tertiary Care Center. Ocul Immunol Inflamm. 2017 Oct;19:1–6.
   Google Scholar
• Botero Aguirre J, Restrepo Hamid A, Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database Syst Rev. 2015;(11). Art. No.: CD010481.
   PubMed Web of Science ®Google Scholar
• Branch RA. Prevention of amphotericin B—induced renal impairment: a review on the use of sodium supplementation. Arch Intern Med. 1988 Nov 1;148(11):2389–2394.
   PubMed Web of Science ®Google Scholar
• Ericksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomized controlled trial. BMJ. 2001;322:1–6.
   PubMedGoogle Scholar
• Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother. 2004 Oct 1;54(4):803–808.
   PubMed Web of Science ®Google Scholar
• Mayer J, Doubek M, Doubek J, et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis. 2002 Aug 1;186(3):379–388.
   PubMed Web of Science ®Google Scholar
• Oto OA, Paydas S, Disel U, et al. Amphotericin B deoxycholate (d‐AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication. Mycoses. 2007 Mar 1;50(2):135–139.
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, Gant V, McKenzie C, et al. A cost‐effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UK. Eur J Haematol. 2007 Jun 1;78(6):532–539.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin. 2008 Jun 1;24(6):1743–1753.
   PubMed Web of Science ®Google Scholar
• Ostermann H, Solano C, Jarque I, et al. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain. BMC Pharmacol Toxicol. 2014 Dec;15(1):52.
   PubMedGoogle Scholar